HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies

[Image: see text] CCT251236 1, a potent chemical probe, was previously developed from a cell-based phenotypic high-throughput screen (HTS) to discover inhibitors of transcription mediated by HSF1, a transcription factor that supports malignancy. Owing to its activity against models of refractory hum...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasqua, A. Elisa, Sharp, Swee Y., Chessum, Nicola E. A., Hayes, Angela, Pellegrino, Loredana, Tucker, Michael J., Miah, Asadh, Wilding, Birgit, Evans, Lindsay E., Rye, Carl S., Mok, N. Yi, Liu, Manjuan, Henley, Alan T., Gowan, Sharon, De Billy, Emmanuel, te Poele, Robert, Powers, Marissa, Eccles, Suzanne A., Clarke, Paul A., Raynaud, Florence I., Workman, Paul, Jones, Keith, Cheeseman, Matthew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150365/
https://www.ncbi.nlm.nih.gov/pubmed/37017629
http://dx.doi.org/10.1021/acs.jmedchem.3c00156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150365/
https://www.ncbi.nlm.nih.gov/pubmed/37017629
http://dx.doi.org/10.1021/acs.jmedchem.3c00156

Ejemplares similares